9th Annual Conference on Biosimilars & Biobetters

9th Annual Conference on Biosimilars & Biobetters is organized by SMi Group and will be held during Sep 26 - 27, 2018 at Copthorne Tara Hotel London Kensington, London, England, United Kingdom.

Who Should Attend?
Chief Executives, Vice Presidents, Executive Directors, Directors, Heads, Managers and Specialists from the following, but not limited to, sectors should attend:
• Biosimilars / Biologics
• Biopharmaceuticals
• Research and Development
• Legal Affairs
• Intellectual Property
• Regulatory Compliance
• Quality affairs and control
• Pharmacovigilance, Drug Safety and Risk Management
• Business Development
• Commercialisation
• Marketing and sales

Conference Overview:
Following the success of our previous events in both UK and USA, Biosimilars and Biobetters UK 2018 will deliver a stellar speaker line-up and bring together a global audience of biosimilar experts to discuss the latest developments and future of the rapidly evolving and expanding biosimilars market.

After over a decade, the biosimilars industry is finally reaching a stage where key stakeholders understand and accept biosimilars. This is reflected in more tolerant legislation and an increased uptake of biosimilars across the globe.

We are now entering a very exciting time, for over the next few years several originator patents are expiring, and we will see a new wave of biosimilars enter the market. Will the originator dominate or will the biosimilar be a successful contender and spark a competitive environment? Have we done enough to convince the payer, prescriber and patient to switch?

Prices:
Conference and 2 Workshops: GBP 2697.0
Conference only: GBP 1499.0
2 Workshops: GBP 1198.0
Conference and 1 Workshop: GBP 2098.0
1 Workshop only: GBP 599.0

Speakers: Michel Mikhail, Global Expert in Biosimilars, Erin Federman, Head of Biologics, Europe, Mylan, Richard Trollope, Head of Biosimilars, Mundipharma International, Richard Peck, Vice President Regulatory Affairs, Lupin, Mourad Farouk Rezk, Senior Director, Global Head Medical Affairs Biosimilars, Biogen, Michael Muenzberg, Member, Comparative Outcomes Group and Former EU Medical Director, Biosimilars, Amgen, Daotian Fu, General Manager, Livzon Mabpharma, Rudiger Jankowsky, Managing Director, Cinfa Biotech, Uwe Gudat, Head of Clinical Safety and Pharmacovigilance, Fresenius-Kabi, Ekkehard Brockstedt, Team Leader Outsourced Trials, Boehringer Ingelheim, Meenu Wadhwa, Section Leader, Cytokines and Growth Factors, Biotherapeutics Group, NIBSC, MHRA

Time: 8:30 am to 4:30 pm

Additional details will be posted as soon as they are available.